Pilocarpine formulation in novel dispenser improves near vision in study
Click Here to Manage Email Alerts
ORLANDO – Use of Eyenovia’s MicroLine resulted in a three-line or more improvement in distance corrected near visual acuity in a statistically significant proportion of study subjects, according to a company representative.
April Jasper, OD, medical monitor for Eyenovia’s studies, shared with Primary Care Optometry News/Healio here at Vision Expo East five key points from the VISION-1 study, which evaluated the safety and efficacy of 1% and 2% pilocarpine with microarray print formulation vs. placebo.
Patients in one of the active arms who received MicroLine, a proprietary microdosed formulation of pilocarpine for presbyopia delivered via the company’s Optejet dispenser, experienced in a 3-line or more improvement at 2 hours post dosing compared with the placebo group.
During the study exit survey, Jasper said 70% of patients stated that they were interested in using the product four to seven times a week should it become available.
She also noted that side effects were transient and mild, and ocular comfort was good, both no different than with placebo.
The VISION-2 study will begin by the end of the year and evaluate one of the doses from the VISION-1 study, Jasper said.
“When patients first come into the practice with trouble seeing close up, the first thing that they’re offered is reading glasses – and that’s the last thing they want,” Jasper said. “I love that we will have another option in our offerings for them. It can be used whenever they want. It won’t replace reading glasses, but it can be another option on certain occasions. I love giving patients choices.”
Jasper said some patients have come into her practice already knowing that something is on the horizon.
“We think it also could be good for overall eye health because some people don’t normally come in for eye exams because they’ve had great vision until now,” she added.
Collapse
Read more about
Click Here to Manage Email Alerts